Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Peripheral T-cell lymphoma (PTCL) presents a poor prognosis with limited therapeutic strategies.
• Epigenetic dysregulation is increasingly recognized in PTCL, suggesting sensitivity to histone deacetylase (HDAC) inhibitors.
• HDAC inhibitors have shown efficacy in T-cell malignancies.

Purpose of the Study:

• To review the development and clinical application of belinostat for PTCL.
• To detail the mechanism of action, clinical trials, and toxicity of belinostat.
• To discuss the significance of the BELIEF trial and belinostat's FDA approval.

Main Methods:

• Review of pivotal clinical trials, including Phase I/II studies in hematologic malignancies, cutaneous T-cell lymphoma (CTCL), and PTCL.
• Detailed examination of the BELIEF trial data for belinostat in relapsed or refractory PTCL.
• Analysis of belinostat's mechanism of action and safety profile.

Main Results:

• Belinostat demonstrated significant activity in T-cell neoplasms.
• The BELIEF trial provided pivotal data supporting belinostat's efficacy in relapsed/refractory PTCL.
• Belinostat has received FDA approval for this indication.

Conclusions:

• Belinostat represents a new therapeutic option for patients with relapsed or refractory PTCL.
• Understanding the epigenetic basis of PTCL supports the use of HDAC inhibitors like belinostat.
• Further research may explore belinostat's role in other T-cell lymphomas.